ORXE has dropped about twenty cents a share, or about 25%
over the past three or four weeks. I have seen no news
from Ore, although the WSJ brought up this today:
TRANSGENOMIC Inc. (Omaha, Neb.) -- This global biotechnology
company named Eric Kaldjian chief scientific officer,
effective immediately. Mr. Kaldjian, 46, succeeds Craig
Tuttle, who was serving in the interim. Mr. Tuttle, 55,
continues as president and chief executive. Mr. Kaldjian was
executive director, medical sciences at Gene Logic, Inc., now
Ore Pharmaceuticals Inc.
---
I would guess that ORXE has net tangible assets now of $30M,
so it is a little sickening that it has a marketcap 30% below
that. I need more than a double just to be even on this
stinker. Owning this has been about as bad as my experience
with Genset--or even Ariad before they got out of their toxic
convertible. |
